As COVID-19 continues to affect communities around the world, we’re working to provide R&D, commercialisation and open innovation teams in industry with access to the next generation of academic research addressing the pandemic. In our second open call for research (details of our first can be found here), we invite companies working on COVID related products and interventions to view the latest research submitted by universities and researchers from around the world in response to the call and to begin a dialogue with the academic teams behind them around collaborative development, licensing and deployment of new pandemic interventions.

What types of research are being submitted to the call?

The research and technologies submitted either directly or indirectly address the spread of SARS-CoV-2 and treatment of COVID-19. This includes diagnostics, therapeutics, vaccines, drug delivery and infection prevention. We are also receiving submissions from researchers studying long covid, next-generation vaccines and therapeutics, ways to measure and predict long-term immunity, as well as the impacts on society, psychology and the environment, and preparing for the next pandemic.

Details about the call to academic teams can be found here

How to access the open call for research responses:

All of the research submitted by universities and academics will be hosted on our free-to-access online matchmaking platform.

If you’re already registered to IN-PART, you can:

IN-PART Blog - Call for research - university covid-19 research - button 1

If you’re new to us (this takes less than a minute)… 

IN-PART blog - Call for Research - university covid-19 research - button 2

And for either of the above, let us know that your company is working on COVID-19 products or interventions and our team will contact you to make sure you’re sent all the projects that align with your interests and requirements.

IN-PART blog - Call for Research - university covid-19 research - button 3

Our platform is completely free to use to make connections with universities who are showcasing their research and technologies to industry. There are no associated costs or finders fees associated with starting conversations with academic teams about any projects through IN-PART.

How does this follow on from our previous open call?

With this call, along with providing a clear pathway for the commercialisation and deployment of COVID-19 interventions, we’re looking to create an open-source of active COVID-19 research that can be accessed by industry R&D professionals, and to provide a level playing field for global universities, researchers and companies to collaborate regardless of size or location. University submissions will reflect on the continuing advancement of the response to the ongoing pandemic, as well as new approaches addressing the impacts and previously unforeseen aspects of this global challenge.

In March last year, we launched our first open call for COVID-19 research as universities and industries pivoted their focus to address the global pandemic. We received 174 submissions from 61 universities and research institutes across the world.

Previous submissions covered everything from responsive antiviral biomaterials (University of Toronto), serological assays (University of Hong Kong) and early warning systems for post-intensive care deterioration (University of Oxford), to point-of-care diagnostics (Cornell University), therapeutic agents (University of Sao Paulo) and first-in-class RNA vaccines (Max Planck Society).

Over 60 conversations are now underway between teams in academia and industry to further develop and deploy the solutions submitted to our call for research. These are being hosted by the likes of Merck, Roche, AbbVie, Ford, Philips, Thermo Fisher and GSK Vaccines, along with many others.

The call is being run in partnership with PraxisAuril, a professional association for knowledge exchange professionals, to help extend the network of universities and institutes we can reach with it. 


Written by Ruth Kirk. Edited by Alex Stockham.

Copyrights reserved unless otherwise agreed – IN-PART Publishing Ltd., 2021: ‘View the latest research, innovation and technology from academics and institutes addressing COVID-19′

About IN-PART:

We believe brilliant connections can solve real-world problems. We match research pioneers from academia with decision-makers in industry sectors striving for a greater positive impact.

Our goal is to enable connections from around the world to match academic research with industry on a level playing field. Through our intelligent, matchmaking platform we showcase leading university innovations and connect academics with an international community of decision-makers in industry, creating meaningful dialogue and partnership.


IN-PART, a digital partnering platform for university-industry collaboration.

250+ universities and research institutes around the world currently showcase their research and innovation on IN-PART to find new collaboration partners in industry. R&D teams get free access to the platform (create an account here). There are no hidden costs and we don’t claim downstream success fees.

Discover, a bespoke scouting service for open innovation.

Through Discover, corporate R&D teams can leverage our extended academic network, which reaches multiple teams across 1,200+ universities and research institutes worldwide. In response to a specific research requirement or challenge, Discover enables R&D teams to identify new opportunities for commercialisation or to solicit proposals for new research.

Interested in speaking with our Discover team? Request a demo |  TTO or academic? Sign-up for weekly Discover emails.


IN-PART Blog - Call for Reserch - University covid-19 research header imageIN-PART Blog - Call for Reserch - University covid-19 research header imageIN-PART Blog - Call for Reserch - University covid-19 research header image

Image credit: CDC / Unsplash Licence